4.7 Article

HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide

期刊

BLOOD
卷 139, 期 10, 页码 1452-1468

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2021013443

关键词

-

资金

  1. National Institutes of Health (NIH), National Cancer Institute (NCI) [AI069197, CA100019, CA218285]
  2. Public Health Service from the NIH/NCI [U24CA076518]
  3. NIH/National Heart, Lung and Blood Institute (NHLBI)
  4. NIH/National Institute of Allergy and Infectious Diseases (NIAID) from the Health Resources and Services Administration (HRSA) [HHSH250201700006C]
  5. Office of Naval Research [N00014-20-1-2705, N00014-20-1-2832]
  6. Biomedical Advanced Research and Development Authority (BARDA)
  7. Be the Match Foundation
  8. Medical College of Wisconsin the National Marrow Donor Program
  9. Actinium Pharmaceuticals, Inc
  10. Adienne SA
  11. Allovir, Inc
  12. Amgen, Inc
  13. Angiocrine Bioscience
  14. Astellas Pharma US
  15. bluebird bio, Inc
  16. Bristol Myers Squibb Co
  17. Celgene Corp
  18. CSL Behring
  19. CytoSen Therapeutics, Inc.
  20. Daiichi Sankyo Co, Ltd
  21. ExcellThera
  22. Fate Therapeutics
  23. GamidaCell, Ltd
  24. Genentech, Inc
  25. Incyte Corporation
  26. Janssen/Johnson Johnson
  27. Jazz Pharmaceuticals, Inc
  28. Kiadis Pharma
  29. Kite, a Gilead Company
  30. Kyowa Kirin
  31. Legend Biotech
  32. Magenta Therapeutics
  33. Merck Sharp Dohme Corp
  34. Millennium, the Takeda Oncology Co
  35. Miltenyi Biotec, Inc
  36. Novartis Pharmaceuticals Corporation
  37. Omeros Corporation
  38. Oncoimmune, Inc
  39. Orca Biosystems, Inc
  40. Pfizer, Inc
  41. Pharmacyclics, LLC
  42. Sanofi Genzyme
  43. Stemcyte
  44. Takeda Pharma
  45. Vor Biopharma
  46. Xenikos BV
  47. [R01AI128775]
  48. [R01HL130388]

向作者/读者索取更多资源

HLA factors play an important role in the success of haploidentical transplantation. Disease-free survival is associated with matching status at individual HLA loci, with HLA-DRB1 and -DPB1 mismatches and HLA-C,-B leader, and -DQB1 matching being favorable. Considering HLA factors may help optimize the selection of haploidentical related donors.
Hematopoietic cell transplantation from HLA-haploidentical related donors is increasingly used to treat hematologic cancers; however, characteristics of the optimal haploidentical donor have not been established. We studied the role of donor HLA mismatching in graft-versus-host disease (GVHD), disease recurrence, and survival after haploidentical donor transplantation with posttransplantation cyclophosphamide (PTCy) for 1434 acute leukemia or myelodysplastic syndrome patients reported to the Center for International Blood and Marrow Transplant Research. The impact of mismatching in the graft-versus-host vector for HLA-A, -B, -C, -DRB1, and -DQB1 alleles, theHLA-B leader, and HLA-DPB1 T-cell epitope (TCE) were studied using multivariable regression methods. Outcome was associated with HLA (mis)matches at individual loci rather than the total number of HLA mismatches. HLA-DRB1 mismatches were associated with lower risk of disease recurrence. HLA-DRB1 mismatching with HLA-DQB1 matching correlated with improved disease-free survival. HLA-B leader matching and HLA-DPB1 TCE-nonpermissive mismatching were each associated with improved overall survival. HLA-C matching lowered chronic GVHD risk, and the level of HLA-C expression correlated with transplant-related mortality. Matching status at the HLA-B leader and HLA-DRB1,-DQB1, and -DPB1 predicted disease-free survival, as did patient and donor cytomegalovirus serostatus, patient age, and comorbidity index. A web-based tool was developed to facilitate selection of the best haploidentical-related donor by calculating disease-free survival based on these characteristics. In conclusion, HLA factors influence the success of haploidentical transplantation with PTCy. HLA-DRB1 and -DPB1 mismatching and HLA-C,-B leader, and -DQB1 matching are favorable. Consideration of HLA factors may help to optimize the selection of haploidentical related donors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据